Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025
09:59am, Sunday, 15'th Jun 2025
The S&P 500 (^GSPC -1.13%) index, the most widely followed index in the stock market, briefly entered bear market territory in April but rebounded in May, much to investors' relief. Yet, although the
TTAM Commits to Comply with Company's Privacy Policy and All Applicable Laws TTAM Commits to Adopting Additional Consumer Protections and Privacy Safeguards to Enhance Protections for Customer Data a
These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025
08:57am, Friday, 13'th Jun 2025
The Nasdaq-100 market index holds a lot of volatile stocks. Some of its top performers seem overvalued today, while others seem to have room for further growth.
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
11:05am, Thursday, 12'th Jun 2025
Shares of Regeneron (REGN 0.44%) have declined this year due to issues with one of its former growth drivers, Eylea, a medicine that treats wet age-related macular degeneration. The therapy is facing
Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research
09:00am, Wednesday, 11'th Jun 2025
Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, privacy concerns over 23andMe's genetic data, importance of biotechnology, and mo
Regeneron Pharma Shares Rise Over 3% After Key Signal
07:48am, Tuesday, 10'th Jun 2025
REGN climbs over 16 points after the alert
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript
12:44pm, Monday, 09'th Jun 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance &
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
09:45am, Thursday, 05'th Jun 2025
REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.
Why Regeneron Is Falling And Why You Should Avoid It
11:19am, Wednesday, 04'th Jun 2025
Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework.
REGN Stock Undervalued At $500?
09:10am, Monday, 02'nd Jun 2025
Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD)
Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster.
07:44am, Monday, 02'nd Jun 2025
Its dermatitis drug could win at least 10% of annual sales in dermatitis by 2030—or about $3 billion.
Regeneron's weight-loss drug helps preserve muscle mass in study
07:12am, Monday, 02'nd Jun 2025
Regeneron Pharmaceuticals said on Monday its experimental weight-loss drug combination helped preserve muscle mass in a mid-stage study.
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
07:05am, Monday, 02'nd Jun 2025
New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p
